Yu-Hsuan Chuang1, Ake T Lu2, Kimberly C Paul1, Aline D Folle1, Jeff M Bronstein3, Yvette Bordelon3, Steve Horvath2,4, Beate Ritz1,3,5. 1. Department of Epidemiology, Fielding School of Public Health (FSPH), University of California Los Angeles (UCLA), Los Angeles, CA, USA. 2. Department of Human Genetics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. 3. Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. 4. Department of Biostatistics, FSPH, UCLA, Los Angeles, CA, USA. 5. Department of Environmental Health, FSPH, UCLA, Los Angeles, CA, USA.
Abstract
BACKGROUND: DNA methylation studies in Parkinson's disease (PD) thus far have focused on disease susceptibility but not progression. OBJECTIVE: In this epigenome-wide association study (EWAS), we aim to identify methylation markers associated with faster cognitive decline or motor progression in PD. METHODS: We included 232 PD patients from the Parkinson's Environment and Gene follow-up study who provided blood samples at enrolment. Information on cognitive and motor function was collected using the Mini-Mental State Examination (MMSE) and Unified Parkinson's Disease Rating Scale (UPDRS). For EWAS analyses, we used a robust measure of correlation: biweight midcorrelations, t-tests, and Cox proportional hazard models. We also conducted weighted correlation network analysis (WGCNA) to identify CpG modules associated with cognitive decline or motor progression in PD. RESULTS: Among 197 individuals of European ancestry, with our EWAS approach we identified 7 genome-wide significant CpGs associated with a MMSE 4-point decline and 8 CpGs associated with faster motor progression (i.e., rate of UPDRS increase ≥5-point/year). The most interesting CpGs for cognitive decline include cg17445913 in KCNB1 (cor = 0.36, p = 6.85×10-7) and cg02920897 in DLEU2 (cor = 0.34, p = 3.23×10-6), while for motor progression it was cg01754178 in PTPRN2 (cor = - 0.34, p = 2.07×10-6). In WGCNA, motor progression related modules were enriched for genes related to neuronal synaptic functions, Wnt signaling pathway, and mitochondrial apoptosis. CONCLUSIONS: Our study provides the first epigenetic evidence that differential methylation in genes previously identified as being associated with cognitive impairment, neuronal synaptic function, Wnt signaling pathway, and mitochondrial apoptosis is associated with cognitive and motor progression in PD.
BACKGROUND: DNA methylation studies in Parkinson's disease (PD) thus far have focused on disease susceptibility but not progression. OBJECTIVE: In this epigenome-wide association study (EWAS), we aim to identify methylation markers associated with faster cognitive decline or motor progression in PD. METHODS: We included 232 PDpatients from the Parkinson's Environment and Gene follow-up study who provided blood samples at enrolment. Information on cognitive and motor function was collected using the Mini-Mental State Examination (MMSE) and Unified Parkinson's Disease Rating Scale (UPDRS). For EWAS analyses, we used a robust measure of correlation: biweight midcorrelations, t-tests, and Cox proportional hazard models. We also conducted weighted correlation network analysis (WGCNA) to identify CpG modules associated with cognitive decline or motor progression in PD. RESULTS: Among 197 individuals of European ancestry, with our EWAS approach we identified 7 genome-wide significant CpGs associated with a MMSE 4-point decline and 8 CpGs associated with faster motor progression (i.e., rate of UPDRS increase ≥5-point/year). The most interesting CpGs for cognitive decline include cg17445913 in KCNB1 (cor = 0.36, p = 6.85×10-7) and cg02920897 in DLEU2 (cor = 0.34, p = 3.23×10-6), while for motor progression it was cg01754178 in PTPRN2 (cor = - 0.34, p = 2.07×10-6). In WGCNA, motor progression related modules were enriched for genes related to neuronal synaptic functions, Wnt signaling pathway, and mitochondrial apoptosis. CONCLUSIONS: Our study provides the first epigenetic evidence that differential methylation in genes previously identified as being associated with cognitive impairment, neuronal synaptic function, Wnt signaling pathway, and mitochondrial apoptosis is associated with cognitive and motor progression in PD.
Authors: Martin J Aryee; Andrew E Jaffe; Hector Corrada-Bravo; Christine Ladd-Acosta; Andrew P Feinberg; Kasper D Hansen; Rafael A Irizarry Journal: Bioinformatics Date: 2014-01-28 Impact factor: 6.937
Authors: Eugene Andres Houseman; William P Accomando; Devin C Koestler; Brock C Christensen; Carmen J Marsit; Heather H Nelson; John K Wiencke; Karl T Kelsey Journal: BMC Bioinformatics Date: 2012-05-08 Impact factor: 3.169
Authors: Evan Gatev; Amy M Inkster; Gian Luca Negri; Chaini Konwar; Alexandre A Lussier; Anne Skakkebaek; Marla B Sokolowski; Claus H Gravholt; Erin C Dunn; Michael S Kobor; Maria J Aristizabal Journal: Nucleic Acids Res Date: 2021-09-20 Impact factor: 16.971
Authors: Chanond A Nasamran; Anubhav Nikunj Singh Sachan; Jennifer Mott; Yuliya I Kuras; Clemens R Scherzer; Harvard Biomarkers Study; Eugenia Ricciardelli; Kristen Jepsen; Steven D Edland; Kathleen M Fisch; Paula Desplats Journal: Alzheimers Dement (Amst) Date: 2021-02-20
Authors: Rebeca Fernández-Carrión; Jose V Sorlí; Oscar Coltell; Eva C Pascual; Carolina Ortega-Azorín; Rocío Barragán; Ignacio M Giménez-Alba; Andrea Alvarez-Sala; Montserrat Fitó; Jose M Ordovas; Dolores Corella Journal: Biomedicines Date: 2021-12-31
Authors: Kimberly C Paul; Alexandra M Binder; Steve Horvath; Cynthia Kusters; Qi Yan; Irish Del Rosario; Yu Yu; Jeff Bronstein; Beate Ritz Journal: BMC Genomics Date: 2021-09-26 Impact factor: 3.969